Skip to main content
Clinical Trials/NCT01645865
NCT01645865
Completed
N/A

Mobile Phone Technology for Prevention of Mother-to-Child Transmission of HIV: Acceptability, Effectiveness, and Cost

Elizabeth Glaser Pediatric AIDS Foundation1 site in 1 country600 target enrollmentMay 2011

Overview

Phase
N/A
Intervention
Not specified
Conditions
HIV
Sponsor
Elizabeth Glaser Pediatric AIDS Foundation
Enrollment
600
Locations
1
Primary Endpoint
The proportion of women who successfully complete key PMTCT transition points from antenatal to six weeks postpartum.
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Although gains have been made in achieving the health-related Millennium Development Goals (MDG), much is still needed in countries affected by high levels of HIV/AIDS. Prevention of mother-to-child transmission (PMTCT) is a cornerstone strategy in reducing infant mortality from HIV. The study will employ a cluster randomized control trial (cRCT) with 26 health facilities randomized to two arms (intervention or control) to determine the effect of mobile phone technology on completion of key PMTCT milestones from antenatal to six weeks postpartum. The study will examine the acceptability, effectiveness, and cost of implementing a PMTCT-focused mHealth strategy among HIV-infected pregnant women, health workers, and male partners.

Registry
clinicaltrials.gov
Start Date
May 2011
End Date
April 2014
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

The proportion of women who successfully complete key PMTCT transition points from antenatal to six weeks postpartum.

Time Frame: ~ 6 months

Initiation of Infant prophylaxis, Facility delivery and receipt of results of 6 weeks early infant diagnosis by DNA PCR

Time Frame: ~ 6 months

Secondary Outcomes

  • Uptake ARV prophylaxis/ART during labor, delivery, and postpartum(~ 6 months)
  • Self-reported maternal adherence to ARV prophylaxis/ART during pregnancy(~ 4 months)
  • Time to initiation of ARV prophylaxis/ART uptake after initial identification of HIV seropositivity within ANC(~ 1 month)

Study Sites (1)

Loading locations...

Similar Trials